[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112015022617A2 - polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável - Google Patents

polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável

Info

Publication number
BR112015022617A2
BR112015022617A2 BR112015022617A BR112015022617A BR112015022617A2 BR 112015022617 A2 BR112015022617 A2 BR 112015022617A2 BR 112015022617 A BR112015022617 A BR 112015022617A BR 112015022617 A BR112015022617 A BR 112015022617A BR 112015022617 A2 BR112015022617 A2 BR 112015022617A2
Authority
BR
Brazil
Prior art keywords
thermostable
recombinant polypeptide
expression vector
immunogenic composition
polypeptide
Prior art date
Application number
BR112015022617A
Other languages
English (en)
Inventor
Jan Haijema Bert
Alexander Maria De Haan Cornelis
Josephus Marie Rottier Petrus
Original Assignee
Mucosis Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mucosis Bv filed Critical Mucosis Bv
Publication of BR112015022617A2 publication Critical patent/BR112015022617A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

resumo “polipeptídeo, composição imunogênica, vetor de expressão recombinante e método de indução de reação imunológica” polipeptídeos recombinantes oligoméricos termoestáveis, que apresentam pelo menos um epítopo antigênico da pré-fusão da proteína f do vírus sincicial respiratório (rsv), que compreende o ectodomínio de proteína f rsv, funcionalidade excluída na região hrb, domínios transmembrana e citoplasmático substituídos por um domínio de trimerização heteróloga e dois locais de divisão furina multibásicos funcionais, são úteis como componentes antigênicos em composições imunogênicas úteis em métodos de indução de reação imunológica e vacinação contra infecções por rsv.
BR112015022617A 2013-03-14 2014-03-12 polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável BR112015022617A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/828,667 US9060975B2 (en) 2013-03-14 2013-03-14 Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
PCT/EP2014/054804 WO2014140083A1 (en) 2013-03-14 2014-03-12 Heat-stable respiratory syncytial virus prefusion f protein oligomers and their use in immunological compositions

Publications (1)

Publication Number Publication Date
BR112015022617A2 true BR112015022617A2 (pt) 2017-10-31

Family

ID=50241453

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022617A BR112015022617A2 (pt) 2013-03-14 2014-03-12 polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável

Country Status (8)

Country Link
US (2) US9060975B2 (pt)
EP (2) EP3178840A1 (pt)
JP (1) JP6285469B2 (pt)
CN (2) CN107029227A (pt)
AU (1) AU2014230822B2 (pt)
BR (1) BR112015022617A2 (pt)
CA (1) CA2905571A1 (pt)
WO (1) WO2014140083A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60056B1 (sr) 2013-02-01 2020-04-30 Medimmune Llc Epitopi f proteina respiratornog sincicijalnog virusa
EP2970981B1 (en) 2013-03-14 2020-10-28 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
BR112018008708A2 (pt) * 2015-10-29 2018-11-06 Univ Emory rsv quimérico, composições imunogênicas e métodos de uso
ES2858315T3 (es) * 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
AU2017272504A1 (en) * 2016-05-30 2018-11-29 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
WO2018130072A1 (zh) * 2017-01-12 2018-07-19 厦门大学 稳定呼吸道合胞病毒融合蛋白的方法
CA3057171A1 (en) 2017-03-30 2018-10-04 The University Of Queensland Chimeric polypeptides containing virus fusion ectodomain and complementary heptad repeats and uses thereof
CN110603262A (zh) 2017-04-04 2019-12-20 华盛顿大学 显示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途
WO2019063844A1 (en) * 2017-09-29 2019-04-04 Universiteit Antwerpen VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
CN109694400A (zh) * 2019-01-31 2019-04-30 苏州高泓利康生物科技有限公司 一种表达呼吸道合胞病毒f蛋白及其制备方法
CN114957407A (zh) * 2019-04-02 2022-08-30 赛诺菲 抗原性多聚呼吸道合胞病毒多肽
CN110054668B (zh) * 2019-04-25 2021-09-10 北京交通大学 一种呼吸道合胞病毒融合前f蛋白及其应用
WO2021046207A1 (en) 2019-09-04 2021-03-11 University Of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN111303245B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
JP2023521183A (ja) * 2020-04-22 2023-05-23 ポステック・リサーチ・アンド・ビジネス・ディヴェロップメント・ファウンデイション 三量体を形成するインフルエンザウイルス表面タンパク質由来組換え赤血球凝集素タンパク質およびその用途
CA3179246A1 (en) * 2020-05-19 2021-11-25 Yves Durocher Use of resistin as a trimerization partner for expression of trimeric proteins
CN112480217B (zh) * 2020-11-30 2022-04-08 广州阿格纳生物医药制造有限公司 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物
WO2024164014A2 (en) * 2023-02-03 2024-08-08 Novavax, Inc. Rsv f vaccine formulations
WO2024192698A1 (zh) * 2023-03-22 2024-09-26 中科牧维(南京)生物科技有限公司 靶向人呼吸道合胞病毒融合糖蛋白的多肽拮抗剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0916726A1 (en) 1997-11-13 1999-05-19 Rijksuniversiteit te Groningen Attaching substances to micro-organisms
CA2450318C (en) 2001-06-11 2011-08-02 Applied Nanosystems B.V. Improved methods for binding acma-type protein anchor fusions to cell-wall material of micro-organisms
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EA023054B1 (ru) 2009-06-24 2016-04-29 Глэксосмитклайн Байолоджикалз С.А. Рекомбинантные антигены pcb
CA2766205A1 (en) 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine comprising at least two paramyxovirus f protein antigens
CN102639147B (zh) * 2009-07-15 2015-11-25 诺华股份有限公司 Rsv f 蛋白组合物和其制作方法
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
ES2535421T3 (es) 2011-03-22 2015-05-11 Mucosis B.V. Composiciones inmunogénicas en forma particulada y métodos para producir las mismas
ES2651143T3 (es) 2011-05-13 2018-01-24 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS

Also Published As

Publication number Publication date
CA2905571A1 (en) 2014-09-18
EP2970393A1 (en) 2016-01-20
JP6285469B2 (ja) 2018-02-28
CN105246910A (zh) 2016-01-13
EP3178840A1 (en) 2017-06-14
AU2014230822B2 (en) 2018-04-12
US9060975B2 (en) 2015-06-23
CN107029227A (zh) 2017-08-11
JP2016510983A (ja) 2016-04-14
EP2970393B1 (en) 2017-01-11
WO2014140083A1 (en) 2014-09-18
AU2014230822A1 (en) 2015-10-01
USRE47471E1 (en) 2019-07-02
US20140271696A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
BR112015022617A2 (pt) polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável
EA201891415A1 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
CL2021001750A1 (es) Receptores quiméricos y metodos de uso de los mismos (divisional solicitud 2677-2020)
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
AU2019349036A8 (en) Immune composition, preparation method therefor, and application thereof
TR201903074T4 (tr) Prostat ile bağlantılı antijenlerin ekspresyonuna yönelik vektörler.
BR112018075032A2 (pt) proteínas de hemaglutinina do vírus influenza e seus uso
BR112016028816A2 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.
MX2018003298A (es) Metodo para preparar una formulacion de proteinas terapeuticas y formulacion de anticuerpos producida por tal metodo.
BR112016019525A2 (pt) construções de proteína uspa2 e seu uso
EA202191622A1 (ru) Стабилизированные растворимые f-белки rsv до слияния
EA202092521A1 (ru) Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека
EA201892735A1 (ru) Состав вакцины против hiv
AR095482A1 (es) Virus del síndrome reproductivo y respiratorio porcino, composiciones, vacuna y métodos de uso
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
BR112013000345A2 (pt) composições antigênicas para vírus sincicial respiratório e métodos
MX2019007349A (es) Vacuna combinada para cerdos.
MX2018016121A (es) Preparacion de anticuerpos monoclonales marcados con 212pb.
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
BR112019001115A2 (pt) proteínas de biofusão como vacinas anti-malária
CL2017003341A1 (es) Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso
MX2019006105A (es) Conjugados de vmen-antigeno y uso de los mismos.
MX2019006104A (es) Conjugados inmunogenicos y uso de los mismos.
MX2017005524A (es) Metodos y composiciones para el virus del dengue recombinante para el desarrollo de vacunas y de diagnostico.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2557 DE 2020-01-07